CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...

Tina Ventura; Chief Investor Relations Officer; Madrigal Pharmaceuticals, Inc. Bill Sibold; Chief Executive Officer & Director; Madrigal Pharmaceuticals, Inc. Mardi Dier; Chief Financial Officer; ...

Researchers say semaglutide, the medication in Ozempic and Wegovy, may help reverse MASH, a progressive liver condition ...